Follow RSS for latest reports on this topicProstate Cancer - Market Research and Reports
Prostate cancer (cancer de prostata)
Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostate cancers.The cancer cells may metastasize (spread) from the prostate to other parts of the body, particularly the bones and lymph nodes. Prostate cancer may cause pain, difficulty in urinating, problems during sexual intercourse, or erectile dysfunction. Other symptoms can potentially develop during later stages of the disease.
Rates of detection of prostate cancers vary widely across the world, with South and East Asia detecting less frequently than in Europe, and especially the United States. Prostate cancer tends to develop in men over the age of fifty and although it is one of the most prevalent types of cancer in men, many never have symptoms, undergo no therapy, and eventually die of other causes. This is because cancer of the prostate is, in most cases, slow-growing, symptom-free, and since men with the condition are older they often die of causes unrelated to the prostate cancer, such as heart/circulatory disease, pneumonia, other unconnected cancers, or old age. About 2/3 of cases are slow growing, the other third more aggressive and fast developing.
Many factors, including genetics and diet, have been implicated in the development of prostate cancer. The presence of prostate cancer may be indicated by symptoms, physical examination, prostate specific antigen (PSA), or biopsy. The PSA test increases cancer detection but does not decrease mortality. Suspected prostate cancer is typically confirmed by taking a biopsy of the prostate and examining it under a microscope. Further tests, such as CT scans and bone scans, may be performed to determine whether prostate cancer has spread.
Prostate cancer symptoms
Men with early prostate cancer are unlikely to have any symptoms, as these only occur when the cancer is large enough to put pressure on the urethra (the tube that drains urine from the bladder). In men over the age of 50, the prostate gland often gets larger due to a non-cancerous condition called benign prostatic hyperplasia or hypertrophy (BPH).
Symptoms of prostate cancer - signs of prostate cancer of both benign enlargement of the prostate gland and malignant tumours (cancer) are similar and can include any of the following:
- difficulty passing urine
- passing urine more frequently than usual, especially at night
- pain when passing urine
- blood in the urine (this is not common).
If you have any of these symptoms it’s important to get them checked by your doctor. But remember, most enlargements of the prostate are not cancer.
Prostate Cancer treatment
Treatment options for prostate cancer with intent to cure are primarily surgery, radiation therapy, and proton therapy. Other treatments, such as hormonal therapy, chemotherapy, cryosurgery, and high intensity focused ultrasound (HIFU) also exist, depending on the clinical scenario and desired outcome.
The age and underlying health of the man, the extent of metastasis, appearance under the microscope, and response of the cancer to initial treatment are important in determining the outcome of the disease. The decision whether or not to treat localized prostate cancer (a tumor that is contained within the prostate) with curative intent is a patient trade-off between the expected beneficial and harmful effects in terms of patient survival and quality of life.
Related Reports:
We found over 40 reports that matched your search.
Next 40 Matches >Refine your search, and find more matches, using the form above.
Prostate Cancer - Pipeline Review, H1 2018 [Report Updated: 29-06-2018]
Prostate Cancer - Pipeline Review, H1 2018SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prostate Cancer - Pipeline Review, H1 2018, provides an overview of the Prostate Cancer (Oncology) pipeline landscape.Prostate cancer is a form of cancer that affects men and starts off in the prostate gland. Prostate cancer usually occurs in older men. Symptoms incl...Read More >>>
Published:
2018-06-29
Published by: Global Markets Direct
Prices Starting From:
$2500
Global Prostate Cancer Partnering 2012 to 2018 [Report Updated: 01-03-2018]
Global Prostate Cancer Partnering Terms and Agreements since 2012 report provides the reader with the following key benefits:
• In-depth understanding of deal trends since 2012
• Access to headline, upfront, milestone and royalty data
• Comprehensive access to multiple deals entered into by the world’s biopharma companies since 2012
• Insight into key deal terms included inRead More >>>
Published:
2018-03-01
Published by: Current Partnering
Prices Starting From:
$1495
Metastatic Hormone Refractory Prostate Cancer - Pipeline Insight, 2018 [Report Updated: 14-02-2018]
Metastatic Hormone Refractory Prostate Cancer - Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Metastatic Hormone Refractory Prostate Cancer development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple s...Read More >>>
Published:
2018-02-14
Published by: Delve Insight
Prices Starting From:
$1500
Metastatic Prostate Cancer - Pipeline Insight, 2018 [Report Updated: 14-02-2018]
Metastatic Prostate Cancer - Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Metastatic Prostate Cancer development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis...Read More >>>
Published:
2018-02-14
Published by: Delve Insight
Prices Starting From:
$1250
Metastatic Hormone Refractory Prostate Cancer - Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]
DelveInsight's Metastatic Hormone Refractory Prostate Cancer - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the Metastatic Hormone Refractory Prostate Cancer epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027. Markets Covered• United States• EU5 (Germany, France, Italy, Spain, and the United Kingdo...Read More >>>
Published:
2018-02-14
Published by: Delve Insight
Prices Starting From:
$3250
Metastatic Prostate Cancer - Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]
DelveInsight's Metastatic Prostate Cancer - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the Metastatic Prostate Cancer epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027. Markets Covered• United States• EU5 (Germany, France, Italy, Spain, and the United Kingdom)• Japan Study Period: 2016-2027 Me...Read More >>>
Published:
2018-02-14
Published by: Delve Insight
Prices Starting From:
$3250
Prostate cancer -Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]
DelveInsight's Prostate cancer - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the Prostate cancer epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027. Markets Covered• United States• EU5 (Germany, France, Italy, Spain, and the United Kingdom)• Japan Study Period: 2016-2027 Prostate cancer Epidemiol...Read More >>>
Published:
2018-02-14
Published by: Delve Insight
Prices Starting From:
$3250
Prostate Cancer: Update Bulletin [January 2018] [Report Updated: 01-01-2018]
This edition presents key opinion leader (KOL) views on recent developments in the prostate cancer market. Topics covered include: Pfizer and Astellas’ announcement in September 2017 that the Phase III PROSPER study evaluating Xtandi (enzalutamide) plus androgen deprivation therapy (ADT) in patients with non-metastatic castration-resistant prostate cancer (CRPC) met its primary endpoint of impro...Read More >>>
Published:
2018-01-01
Published by: FirstWord Pharma
Prices Starting From:
$1095
Global Prostate Cancer Partnering 2010 to 2017 [Report Updated: 01-11-2017]
Global Prostate Cancer Partnering Terms and Agreements since 2010 report provides the reader with the following key benefits:
• In-depth understanding of deal trends since 2010
• Access to headline, upfront, milestone and royalty data
• Comprehensive access to multiple deals entered into by the world’s biopharma companies since 2010
• Insight into key deal terms included inRead More >>>
Published:
2017-11-01
Published by: Current Partnering
Prices Starting From:
$1495
EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026 [Report Updated: 01-11-2017]
EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026SummaryProstate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in males. Worldwide, about 1.1 million men were diagnosed with prostate cancer in 2012. Diagnosed incident cases of prostate cancer is defined as malignant neoplasms with the prostate gland as the primary site (IC...Read More >>>
Published:
2017-11-01
Published by: Global Data
Prices Starting From:
$3995
Prostate cancer -Epidemiology Forecast to 2025 [Report Updated: 10-10-2017]
DelveInsight “Prostate cancer - Epidemiology Forecast To 2025” provides an overview of the epidemiology trends of Prostate cancer in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Prostate cancer prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevaili...Read More >>>
Published:
2017-10-10
Published by: Delve Insight
Prices Starting From:
$2750
Prostate Cancer [2017] [Report Updated: 01-10-2017]
How will established and emerging agents reshape the prostate cancer treatment landscape? A multitude of novel therapies have been approved for prostate cancer over the past ten years, but what does the future hold? Key opinion leaders (KOLs) are excited about expanded approvals for hormonal therapies and personalised approaches with PARP inhibitors and PD-1/PD-L1 immunotherapies, but which therap...Read More >>>
Published:
2017-10-01
Published by: FirstWord Pharma
Prices Starting From:
$8145
China Molecular Diagnostics Market, Test Volume & Forecast by Oncology Test (Breast Cancer, Colorectal Cancer, Prostate Cancer) Infectious Disease Test (Virology, HPV), Genetic Test (Blood Screening, HLA) [Report Updated: 28-08-2017]
China molecular diagnostics market is expected to be more than USD 1.5 Billion by the year 2022. As a part of the evolution of medicine in China; en route for targeted therapy and recognizing the revenue as well as profits in this new market, Diagnostics instruments are the foundation of the biotechnology industry and the pharmaceutical industry are appropriately important in molecular diagnostics...Read More >>>
Published:
2017-08-28
Published by: Renub
Prices Starting From:
$1200
Metastatic Hormone Refractory Prostate Cancer - Pipeline Insight, 2017 [Report Updated: 31-07-2017]
DelveInsight’s, “Metastatic Hormone Refractory Prostate Cancer-Pipeline Insights, 2017”, report provides comprehensive insights of the ongoing therapeutic research and development across Metastatic Hormone Refractory Prostate Cancer. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline...Read More >>>
Published:
2017-07-31
Published by: Delve Insight
Prices Starting From:
$1500
Metastatic Prostate Cancer - Pipeline Insight, 2017 [Report Updated: 31-07-2017]
DelveInsight’s, “Metastatic Prostate Cancer-Pipeline Insights, 2017”, report provides comprehensive insights of the ongoing therapeutic research and development across Metastatic Prostate Cancer. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Metastatic...Read More >>>
Published:
2017-07-31
Published by: Delve Insight
Prices Starting From:
$1250
Metastatic Hormone Refractory Prostate Cancer - Epidemiology Insights to 2025 [Report Updated: 31-07-2017]
DelveInsight’s “Metastatic Hormone Refractory Prostate Cancer -Epidemiology Forecast, 2025” provides an overview of the epidemiology trends of Metastatic Hormone Refractory Prostate Cancer in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Metastatic Hormone Refractory Prostate Cancer. The Report also ...Read More >>>
Published:
2017-07-31
Published by: Delve Insight
Prices Starting From:
$2950
Metastatic Prostate Cancer - Epidemiology Insights to 2025 [Report Updated: 31-07-2017]
DelveInsight’s “Metastatic Prostate Cancer -Epidemiology Forecast, 2025” provides an overview of the epidemiology trends of Metastatic Prostate Cancer in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Metastatic Prostate Cancer. The Report also discusses the prevailing risk factors, disease burden wit...Read More >>>
Published:
2017-07-31
Published by: Delve Insight
Prices Starting From:
$2950
Oncology Drugs Market Global Report 2017 Including: Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Non-Small Cell Lung Cancer , Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Cancer, Cervical Cancer, Blood Cancer, Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicula [Report Updated: 17-07-2017]
Oncology Drugs market covers drugs that are used in the treatment of a wide range of cancer, sarcoma, and tumor. Some of the bestselling oncology drugs in 2016 include Avastin, Herceptin, Revlimid, MabThera/Rituxan, Gleevac/Glivec, Alimta, Zytiga, Tasigna, Sandostatin, and Afinitor.
The global oncology drugs market was estimated to be around 8 billion as of 2016. The oncology drugs market market made up around 11% Read More >>>
Published:
2017-07-17
Published by: The Business Research Company
Prices Starting From:
$4000
Prostate Cancer [2016]: Bulletin #3 [Report Updated: 01-07-2017]
Gain new key opinion leader (KOL) insights on the latest events happening in prostate cancer.Topics covered include expert opinions on; the results of the Phase III LATITUDE and STAMPEDE trials investigating J&J’s Zytiga (abiraterone) plus prednisone, in combination with androgen deprivation therapy (ADT) in patients with hormone-naïve prostate cancer (HNPC); KOL views on the results published ...Read More >>>
Published:
2017-07-01
Published by: FirstWord Pharma
Prices Starting From:
$1045
Prostate Cancer - Pipeline Review, H1 2017 [Report Updated: 30-06-2017]
Prostate Cancer - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prostate Cancer - Pipeline Review, H1 2017, provides an overview of the Prostate Cancer (Oncology) pipeline landscape.Prostate cancer is a form of cancer that affects men and starts off in the prostate gland. Prostate cancer usually occurs in older men. Symptoms incl...Read More >>>
Published:
2017-06-30
Published by: Global Markets Direct
Prices Starting From:
$2500
Cancer Immunotherapy Market by Technology (Monoclonal Antibodies, Cytokines & Immunomodulators, and Others), by Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Others) by End User (Hospitals, Cancer Research Centers, and Clinics) - Global Opportunity Analysis and Industry Forecast, 2014-2022 [Report Updated: 18-05-2017]
CHAPTER 1 INTRODUCTION1.1. REPORT DESCRIPTION1.2. KEY BENEFITS1.3. KEY MARKET SEGMENT1.4. RESEARCH METHODOLOGY1.4.1. Secondary research1.4.2. Primary research1.5. ANALYST TOOLS AND MODELSCHAPTER 2 EXECUTIVE SUMMARY2.1. KEY FINDINGS OF THE STUDY2.2. CXO PERSPECTIVECHAPTER 3 MARKET OVERVIEW3.1. MARKET DEFINITION AND SCOPE3.2. KEY FINDINGS3.2.1. Top investment pockets3.2.2. Top winning strategies3.3....Read More >>>
Published:
2017-05-18
Published by: Allied Market Research
Prices Starting From:
$5370
Prostate Cancer [2016]: Bulletin #2 [Report Updated: 01-05-2017]
Gain new key opinion leader (KOL) insights on the latest events happening in prostate cancer. Topics covered include expert opinions on the two oral PARP inhibitors (AstraZeneca’s Lynparza [olaparib] and Clovis Oncology’s rucaparib) that are in Phase III development for men with metastatic castration-resistant prostate cancer (mCRPC). KOLs also provide their first insights on the IMbassador250...Read More >>>
Published:
2017-05-01
Published by: FirstWord Pharma
Prices Starting From:
$1045
Prostate Cancer: Update Bulletin [April 2017] [Report Updated: 01-04-2017]
Gain new KOL insights on the latest events happening in prostate cancer (PC). In December 2016, Pfizer and Astellas Pharmaceuticals announced the Phase IV PLATO study, evaluating continued treatment with Xtandi plus Zytiga and prednisone as compared to treatment with Zytiga and prednisone alone, did not meet its primary endpoint of improvement in progression-free survival (PFS) in patients with ch...Read More >>>
Published:
2017-04-01
Published by: FirstWord Pharma
Prices Starting From:
$1045
Global Prostate Cancer Diagnostics Market 2012- 2022 [Report Updated: 01-04-2017]
SummaryBased on products type, the report describes major products type share of regional market. Products mentioned as follows: By Type Tumor Biomarker Tests Imaging BiopsyBased on region, the report describes major regions market by vendor, products and Application. Regions mentioned as follows: Europe North America China Japan & KoreaBased on Application, the report descri...Read More >>>
Published:
2017-04-01
Published by: HeyReport
Prices Starting From:
$1880
Prostate Cancer - Pipeline Review, H2 2016
Prostate Cancer - Pipeline Review, H2 2016SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prostate Cancer – Pipeline Review, H2 2016, provides an overview of the Prostate Cancer (Oncology) pipeline landscape.Prostate cancer is a form of cancer that affects men and starts off in the prostate gland. Prostate cancer usually occurs in older men. Symptoms in...Read More >>>
Published:
2016-12-21
Published by: Global Markets Direct
Prices Starting From:
$2500
Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecules (Genetic Biomarkers, Protein Biomarkers, and Glycoprotein Biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer, and Other Cancers), Application (Diagnostics, Drug Discovery and Development, Prognosti [Report Updated: 01-12-2016]
Cancer biomarkers are biomolecules that specifies the existence of cancer or cancerous cells in the body. These are generally molecules that are released due to the presence of a tumor or a particular indication in the body to the presence of cancer. These molecules are densely distributed in tissues, urine, serum, blood, and other body fluids. Their expression levels serve as the basis or indicat...Read More >>>
Published:
2016-12-01
Published by: Allied Market Research
Prices Starting From:
$5370
Global Prostate Cancer Partnering 2010 to 2016
Provides understanding and access to the prostate cancer partnering deals and agreements entered into by the worlds leading healthcare companies .
Read More >>>Published:
2016-11-01
Published by: Current Partnering
Prices Starting From:
$1495
Prostate Cancer: KOL Insight 2016 [Report Updated: 01-11-2016]
PARP inhibitors and second-generation hormonal therapies driving KOL excitementGood news for late-stage prostate cancer patients: a host of new therapies are in the pipeline, indications for mainstay drug classes are expanding, and personalized treatment may be just around the corner. Find out how doctors and manufacturers are dealing with a fast-evolving treatment algorithm and more intense compe...Read More >>>
Published:
2016-11-01
Published by: FirstWord Pharma
Prices Starting From:
$7900
Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021
The global cancer immunotherapy market is expected to reach USD 119.39 billion by 2021 from USD 61.97 billion in 2016, at a CAGR of 14.0% from 2016 to 2021. Factors such as increasing incidence of cancer, rising healthcare expenditure, and increased access to medical insurance in developed countries are driving growth in the caner immunotherapy market. However, stringent regulatory policies and si...Read More >>>
Published:
2016-09-15
Published by: MarketsandMarkets
Prices Starting From:
$5650
Prostate Cancer - Heat Map and Analysis
Prostate Cancer - Heat Map and AnalysisSummaryProstate cancer (PC) is a type of cancer that affects the prostate gland of the male reproductive system, and is the most common non-cutaneous malignant cancer in men. Internationally, it is the sixth-largest cancer-related cause of death in men. Those aged over 50 are at the greatest risk of developing PC, with advanced age being the primary risk fact...Read More >>>
Published:
2016-09-01
Published by: GBI Research
Prices Starting From:
$2000
Prostate Cancer Forecast in 18 Major Markets 2016-2026 [Report Updated: 01-09-2016]
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Prostate Cancer in 18 Major MarketsProstate cancer is one of the most common cancers in men. The prostate, found only in men, is the size and shape of a walnut and grows bigger with age. It sits underneath the bladder and in front of the rectum. It surrounds part of the urethra which is a tube that carries urine from the bladder...Read More >>>
Published:
2016-09-01
Published by: Black Swan Analysis
Prices Starting From:
$6100
Cancer Hormone Therapy Market: By Therapy Type (Neoadjuvant & Adjuvant Treatment), By Cancer Treated (Breast, Prostate, Ovarian, Thyroid, Kidney & Other Cancers) & By Geography-Forecast (2016-2021) [Report Updated: 26-02-2016]
Hormones are natural substances produced by glands in our bodies. They are carried in our bloodstream and act as messengers between one part of our body and another. Hormone therapy for cancer is the use of medicines to block the effects of hormones which are used by some of the cancers to grow. Cancer hormone therapy does not work for all types of cancer. However doctors and surgeons use hormone ...Read More >>>
Published:
2016-02-26
Published by: Industry ARC
Prices Starting From:
$5250
Prostate Cancer: Update Bulletin [Feb 2016]
IntroductionGain new KOL insights on the latest events with the potential to shape the targeted treatment of Prostate Cancer (PC). Topics covered include opinions about the role of custirsen (OGX-011; OncoGenex/Teva) in combination with Jevtana (cabazitaxel; Sanofi) as a second-line treatment for metastatic castrate-resistant PC (mCRPC), and the development of Lynparza (olaparib; AstraZeneca) as a...Read More >>>
Published:
2016-02-01
Published by: FirstWord Pharma
Prices Starting From:
$995
Prostate Cancer: KOL Insight
IntroductionThe last decade has seen significant change in how prostate cancer is treated. Innovation and lifecycle management have each played a role in shaping today’s treatment paradigm. But how will results from landmark studies such as STAMPEDE and CHAARTED impact current treatment decisions? And which products will emerge victorious in the battle for market share?Prostate Cancer: KOL Insig...Read More >>>
Published:
2015-11-01
Published by: FirstWord Pharma
Prices Starting From:
$7900
Global Prostate Cancer Therapeutics Market to 2020 [Report Updated: 11-05-2015]
Prostate Cancer remains a top priority for health systems around the world as incidence level rises, fueled by growing and aging populations. The main drivers for the prostate cancer market are the increase in the global aging population, innovation in drugs and developments in genomics and proteomics. The prostate cancer market faces some hindrances as well such as the high cost of prostate cance...Read More >>>
Published:
2015-05-11
Published by: iGATE Research
Prices Starting From:
$1000
Prostate Cancer - US Drug Forecast and Market Analysis to 2023
Prostate Cancer - US Drug Forecast and Market Analysis to 2023SummaryProstate cancer is the second most common cancer in men worldwide, after skin cancer. It accounts for 15% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems. While patients diagnosed with early-stage, localized prostate cancer can be cured, patients who are diagnosed with or progress to c...Read More >>>
Published:
2015-04-08
Published by: Global Data
Prices Starting From:
$4995
Prostate Cancer - 5EU Drug Forecast and Market Analysis to 2023
Prostate Cancer - 5EU Drug Forecast and Market Analysis to 2023SummaryProstate cancer is the second most common cancer in men worldwide, after skin cancer. It accounts for 15% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems. While patients diagnosed with early-stage, localized prostate cancer can be cured, patients who are diagnosed with or progress to ...Read More >>>
Published:
2015-04-08
Published by: Global Data
Prices Starting From:
$6995
Prostate Cancer - Current and Future Players
Prostate Cancer - Current and Future PlayersSummaryGlobalData has released its pharma report, “Prostate Cancer - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Prostate Cancer Market. The report identifies and analyses the key companies shaping and driving the global Prostate Cancer market. The ...Read More >>>
Published:
2015-04-08
Published by: Global Data
Prices Starting From:
$2995
KOL Insight: Prostate Cancer: Competition intensifies in race to the top
IntroductionThe Prostate Cancer market has seen a number of progressive changes in recent years. The launches of Johnson & Johnson’s Zytiga (abiraterone acetate) and Medivation/Astellas’s Xtandi (enzalutamide) has reinvigorated the post-chemo treatment segment, while launch of the first cancer vaccine Provenge (sipuleucel-T; Dendreon) and Zytiga’s expanded approval had finally given new opti...Read More >>>
Published:
2013-11-01
Published by: FirstWord Pharma
Prices Starting From:
$7900
Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top
IntroductionCharting the Future Prostate Cancer Market LandscapeThe prostate cancer market has experienced substantial changes in the last five years with patent expiries of key compounds and approvals of new novel therapies. The launch of Zytiga (abiraterone acetate), Medivation/Astellas’ Xtandi (enzalutamide) and Algeta/Bayer’s Xofigo are set to trigger the global prostate cancer market to g...Read More >>>
Published:
2013-11-01
Published by: FirstWord Pharma
Prices Starting From:
$4995
Additional Searches
You may also like to search separately for: Prostate Cancer
